drugset / Trial / NCT01838681
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
Timeline
- Start
- 2013-06
- Primary completion
- 2016-06
- Completion
- 2016-06
Outcome
Missed primary endpoint
registry p = 0.2641; Odds Ratio (OR) 0.83 (95% CI 0.60 to 1.15) NCT01838681 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 1 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 2 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 3 mg | Oral |
| Background | Duloxetine | Small molecule | — | — |
| Background | Escitalopram | Small molecule | — | — |
| Background | Fluoxetine | Small molecule | — | — |
| Background | Paroxetine | Small molecule | — | — |
| Background | Sertraline | Small molecule | — | — |
| Background | Venlafaxine | Small molecule | — | — |